Effect of a soluble prebiotic fiber, NUTRIOSE, on the absorption of ginsenoside Rd in rats orally administered ginseng  by Kim, Kyung-Ah et al.
lable at ScienceDirect
J Ginseng Res 38 (2014) 203e207Contents lists avaiJournal of Ginseng Research
journal homepage: http : / /www.ginsengres.orgResearch articleEffect of a soluble prebiotic ﬁber, NUTRIOSE, on the absorption of
ginsenoside Rd in rats orally administered ginseng
Kyung-Ah Kim1,q, Hye Hyun Yoo 2,q, Wan Gu 1, Dae-Hyung Yu 1, Ming Ji Jin 2,
Hae-Lim Choi 3, Kathy Yuan 4, Laetitia Guerin-Deremaux 5, Dong-Hyun Kim1,*
1Department of Pharmacy, College of Pharmacy, Kyung Hee University, Dongdaemun-gu, Seoul, Korea
2Department of Pharmacy, College of Pharmacy, Hanyang University, Ansan, Gyeonggi-do, Korea
3Roquette Korea Ltd, Teheran-ro, Gangnam-gu, Seoul, Korea
4Roquette Management (Shanghai) Co., Ltd, K. Wah Centre, Shanghai, China
5Biology and Nutrition department, Roquette Frères, Rue de la Haute Loge, Lestrem, Francea r t i c l e i n f o
Article history:
Received 24 December 2013
Received in Revised form
28 March 2014
Accepted 29 March 2014
Available online 21 April 2014
Keywords:
ginsenoside Rb1
ginsenoside Rd
NUTRIOSE
Panax ginseng
pharmacokinetic* Corresponding author. Department of Life and Na
Hoegi, Dongdaemun-ku, Seoul 130-701, Korea.
E-mail address: dhkim@khu.ac.kr (D.-H. Kim).
q
These authors contributed equally.
This is an Open Access article distributed under the t
which permits unrestricted non-commercial use, dist
1226-8453/$ e see front matter Copyright  2014, Th
http://dx.doi.org/10.1016/j.jgr.2014.03.003a b s t r a c t
Background: There is limited understanding of the effect of dietary components on the absorption of
ginsenosides and their metabolites into the blood.
Methods: This study investigated the pharmacokinetics of the ginseng extract and its main constituent
ginsenoside Rb1 in rats with or without pretreatment with a prebiotic ﬁber, NUTRIOSE, by liquid
chromatography tandem mass spectrometry. When ginsenoside Rb1 was incubated with rat feces, its
main metabolite was ginsenoside Rd.
Results: When the intestinal microbiota of rat feces were cultured in vitro, their ginsenoside Rd-forming
activities were signiﬁcantly induced by NUTRIOSE. When ginsenoside Rb1 was orally administered to
rats, the maximum plasma concentration (Cmax) and area under the plasma drug concentrationetime
curve (AUC) for the main metabolite, ginsenoside Rd, were 72.4  31.6 ng/mL and 663.9  285.3 mg$h/
mL, respectively. When the ginseng extract (2,000 mg/kg) was orally administered, Cmax and AUC for
ginsenoside Rd were 906.5  330.2 ng/mL and 11,377.3  4,470.2 mg$h/mL, respectively. When ginseng
extract was orally administered to rats fed NUTRIOSE containing diets (2.5%, 5%, or 10%), Cmax and AUC
were increased in the NUTRIOSE receiving groups in a dose-dependent manner.
Conclusion: These ﬁndings reveal that intestinal microﬂora promote metabolic conversion of ginsenoside
Rb1 and ginseng extract to ginsenoside Rd and promote its absorption into the blood in rats. Its con-
version may be induced by prebiotic diets such as NUTRIOSE.
Copyright  2014, The Korean Society of Ginseng, Published by Elsevier. All rights reserved.1. Introduction
Orally administered herbal medicines and functional foods
inevitably come in contact with intestinal microbiota [1,2]. The
intestinal microbiota are inﬂuenced by endogenous and exoge-
nous factors, such as diet, drugs, stress, etc, and they metabolize
endogenous compounds secreted into the gastrointestinal tract
and orally administered exogenous xenobiotics, such as constitu-
ents of herbal medicines and functional foods [3e5]. Thus,nopharmaceutical Sciences and De
erms of the Creative Commons At
ribution, and reproduction in any
e Korean Society of Ginseng, Publintestinal microbiota transform constituents of herbal medicines
and functional foods to bioactive compounds prior to absorption
[2,6,7].
Ginseng (the root of Panax ginseng Meyer, Araliaceae) is
frequently used as a herbal medicine and functional food, and
ginsenosides, the major constituents, exhibit a spectrum of bio-
logical effects, including anti-inﬂammatory and antitumor activity
[2,8,9]. Ginsenosides need to be metabolically activated by human
intestinal microbes to express their biological effects [10,11].partment of Pharmaceutical Science, College of Pharmacy, Kyung Hee University, 1,
tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)
medium, provided the original work is properly cited.
ished by Elsevier. All rights reserved.
Fig. 1. Metabolic pathway of protopanaxadiol-type ginsenosides metabolized by intestinal bacteria.
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ginsenoside Rd by human intestinal microbiota (Fig. 1) [6,7,12].
Ginsenoside Rd exhibits potent anti-inﬂammatory, antiobesity, and
anti-ischemic effects [13e15], and it is further metabolized to
ginsenoside F2 and compound K, which also possess pharmaco-
logical activity. Intestinal microbes, therefore, play an important
role in the observed pharmacological effects of ginseng. Further-
more, the gastrointestinal absorption of ginseng constituents and
metabolites in humans and animals is inﬂuenced by regulators of
intestinal microbiota such as diet and drugs. Therefore, the effect of
diet and subsequent alterations in intestinal bacterial metabolic
activities on the pharmacokinetic behaviors of ginsenosides needs
to be studied in detail.
NUTRIOSE, used as a food ingredient, is a soluble prebiotic ﬁber
derived from wheat and corn. NUTRIOSE administered orally to
healthy men is partially digested (up to 15%) in the small intestine
and progressively fermented (up to 75%) in the colon [16].
NUTRIOSE also increased colony counts of intestinal Lactobacillus
spp. [16e18]. In human individuals given short- and long-term
NUTRIOSE supplementations, fecal a/b-glucosidase activities were
signiﬁcantly increased and symptoms of intestinal bowel disease
were improved through a protective immune effect.
In the present study, we studied the pharmacokinetics of gin-
senoside Rd after oral administration of ginsenoside Rb1 or ginseng
extract with or without NUTRIOSE pretreatment in rats, to under-
stand the effect of diet on the relationship between intestinal
bacterial metabolic conversion of ginsenosides to ginsenoside Rd
and the absorption of ginsenoside Rd into the blood.
2. Materials and methods
2.1. Materials
Ginseng extract was prepared according to the method
described by Bae et al [12]. Brieﬂy, the dried root of Panax ginseng
Meyer (1 kg) produced at Kumsan (Chungnam, Korea) was
extracted with 70% ethanol twice, concentrated, and freeze-dried
(yield, 18%). The extracted powder contained 8.9% ginsenoside Rb1
and 1.4% ginsenoside Rd. The ethanol extract was suspended in
water and successively extracted with hexane and butanol. The
butanol fraction was separated by silica gel column chromatog-
raphy to yield ginsenosides Rb1 (purity > 92%, 52 mg) and Rd
(purity > 94%, 8 mg).
NUTRIOSE, a mixture of glucose polymers with a fairly narrow
molecular weight range (number-average molecular weight, 200e
4000 Da; weight-averagemolecular weight, 4000e6000; degree ofpolymerization, 12e25), was kindly donated from Roquette (Les-
trem, France).
2.2. Assay of fecal metabolism of ginsenoside Rb1 to ginsenoside Rd
Rat fecal specimens (n ¼ 5, approximately 0.2 g) were collected
in plastic cups and suspended in 1.8 mL cold saline [19]. The fecal
bacterial suspension was centrifuged at 500  g for 5 min, and the
resultant supernatant was sonicated and centrifuged at 10,000  g
for 30 min. The resultant supernatant was used as a crude enzyme
solution.
To investigate the effect of diet on the metabolic activation of
ginsenoside Rb1 to ginsenoside Rd by intestinal microbiota
cultured in Gifu anaerobic broth (GAM broth), the fresh stool
specimenwas suspended in GAM broth and centrifuged at 500  g.
The resultant supernatant was inoculated in dextrose (1%) or
NUTRIOSE (1%) containing GAM broth (glucose-free broth) and
cultured for 24 h. The cultured media was collected by centrifu-
gation (10,000  g, 20 min). The precipitate was used as the crude
enzyme for assaying the metabolism of ginsenoside Rb1 to Rd. The
generated Rd was assayed by high performance liquid chroma-
tography (HPLC).
For assaying the contribution of fecal activity in the metabolism
of ginsenoside Rb1 to ginsenoside Rd, a reaction mixture (2 mL)
containing 0.2 mL of the fecal culture prepared from freshly
collected rat feces (n¼ 5) and 0.2 mL of 0.1mM ginsenoside Rb1was
incubated at 37C for 1 h, which was followed by the addition of
2 mL of MeOH to stop the reaction. The reaction mixture was
centrifuged at 3000  g for 10 min, and the levels of ginsenoside
Rb1 and its metabolite ginsenoside Rd in the resultant supernatant
were analyzed by HPLC. The HPLC systemwas as follows: a Hewlett
Packard series 1050 module, a UV detector (Ramsey, MN, USA) set
at 203 nm, a Hypersil ODS column (4.6  150 mm i.d., 5.0 mm;
Agilent, Santa Clara, CA, USA), linear-gradient mixture of 30% water
and 70% acetonitrile for 15 min as elution solvent, ﬂow rate of
1.0 mL/min, and injection volume of 20 mL.
2.3. Animals
Male SpragueeDawley rats (210e240 g) were supplied by the
Orient Experimental Animal Breeding Center (Gyunggi-do, Korea).
All animals were housed in wire cages (2 rats per cage) kept at a
temperature of 20e22C and 50  10% humidity, fed standard
laboratory chow (Samyang Co., Seoul, Korea), and allowed water ad
libitum. All experiments were performed in accordance with the
National Institutes of Health and Kyung Hee University Guides for
Fig. 2. The metabolic conversion of ginsenoside Rb1 to ginsenoside Rd by rat feces. All
values are presented as mean  standard deviation (n ¼ 5).
Fig. 3. Plasma concentrations of ginsenoside Rd after oral administration of ginseno-
side Rb1 (200 mg/kg) in rats. All values are presented as mean  standard deviation
(n ¼ 5).
Table 1
Pharmacokinetic study of ginsenoside Rd in rats treated with ginsenoside Rb1 or
ginseng extract
Group Ginsenoside Rd
Tmax (h) Cmax (ng/mL) AUC (ng∙h/mL)
Rb0.2 10.6  2.3 72.4  31.6 663.9  285.3
G0.2 9.6  5.3 690.4  473.0 8974.2  379.9
G2 11.2  5.2 906.5  330.2 11377.3  4470.2
N2.5-G2 8.4  5.0 982.2  455.9 12882.3  8086.5
N5-G2 6.0  4.0 1079.5  422.1 12281.0  7062.0
N10-G2 8.0  4.0 1220.3  796.5 15213.3  6086.7
Group labels are as mentioned in Figs. 4 and 5
AUC, area under the blood concentration curve; Cmax, maximum plasma concen-
tration; Tmax, maximum drug concentration time
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2.4. Pharmacokinetic study
Each rat was orally fed ginsenoside Rb1, ginseng extract, or
vehicle 2 h after the last dose of a 2-wk administration of a
NUTRIOSE-containing control diet. Blood was collected (0.2 mL)
from the tail vein at 0 h, 1 h, 2 h, 4 h, 8 h, 12 h, 16 h, 20 h, and 24 h
after ginseng extract administration.
The rats were divided into 2 groups [either treated with vehicle
alone (normal control, n ¼ 5) or test agent (200 mg/kg ginsenoside
Rb1, n ¼ 5)] in a preliminary study and the remaining animals were
later divided into seven groups as follows for a subsequent study:
Group 1, NOR, group fed a control diet, n ¼ 5; Group 2, N-NOR,
group fed NUTRIOSE (control dietþNUTRIOSE 10%, n¼ 5); Group 3,
G0.2, group treated with ginseng extract (200 mg/kg) after feeding
a control diet, n ¼ 5; Group 4, G2, group treated with ginseng
extract (2,000 mg/kg) after feeding a control diet, n ¼ 5; Group 5,
N2.5-G2, group treated with ginseng extract (2,000 mg/kg) after
feeding NUTRIOSE (control diet þ NUTRIOSE 2.5%, n ¼ 5); Group 6,
N5-G2, group treated with ginseng extract (2,000 mg/kg) after
feeding NUTRIOSE (control diet þ NUTRIOSE 5%, n ¼ 5); and Group
7, N10-G2, group treated with ginseng extract (2,000 mg/kg) after
feeding NUTRIOSE (control dietþNUTRIOSE 10%, n¼ 5) in a second
substudy. The control diet or NUTRIOSE-containing control diet
was administered for 2 wk prior to starting treatment with the
ginseng extract.
2.5. Sample preparation and calibration curves
Blood samples were centrifuged for 10 min at 4,000  g to
separate the plasma. The plasma samples (20 mL) were deprotei-
nized with the same volume of acetonitrile for ginsenoside Rd
detection. The supernatants were evaporated to dryness under a
gentle N2 stream at 50C. The residue was reconstituted with
100 mL of 70% methanol. A 2-mL aliquot was injected into the liquid
chromatography tandem mass spectroscopy (LCeMS/MS) system.
Calibration standards were prepared by spiking 10 mL of working
solutions into 90 mL of rat blank plasma over a concentration range
of 5e1,000 ng/mL. The calibration curves were generated by plot-
ting the peak area ratios of the analytes to the internal standard vs.
the concentrations of analytes, by least-square linear regression.
Each standard was prepared in triplicate. The correlationcoefﬁcients of the calibration curves were greater than 0.99. The
calibration curve equation for ginsenoside Rd was
y ¼ 9.94  106x þ 3.8  105.2.6. HPLC-MS/MS instrumentation
For the analysis of ginsenoside Rd, HPLC-MS/MS analyses were
performed on Agilent Technologies 1260 Inﬁnity HPLC-6460 Triple
Quad Mass Spectrometer (Palo Alto, CA, USA). Chromatographic
separation of the sample was performed on a Hypersil BDS C18
column (50 mm  2.1 mm internal diameter, 5 mL; Thermo Scien-
tiﬁc, Waltham, MA, USA). For elution, a linear gradient was applied:
CH3CNeH2O (40:60, v/v) to CH3CNeH2O (95:5, v/v) for 10 min. The
ﬂow rate was 0.3 mL/min. Mass spectra were acquired in a positive
mode using nitrogen gas at a temperature of 300C, ﬂow rate of
10 L/min, nebulizer pressure of 20 psi, quadruple temperature of
30C, and capillary voltage of 4000 V. The precursoreproduct ion
pairs monitored were 969/789 for ginsenoside Rd and 409/238
for the internal standard (amlodipine).2.7. Pharmacokinetic analysis
The maximum plasma concentration (Cmax) and time to reach
maximum drug concentration (Tmax) for ginsenoside Rd were
estimated directly from the plasma concentrationetime proﬁles.
Area under the plasma drug concentrationetime curve (AUC) was
calculated by using the log-linear trapezoidal rule for the total
period and extrapolated to inﬁnity.
Fig. 4. Pharmacokinetic study of ginsenoside Rd in rats orally administered ginseng
extract. Rats were orally administered ginseng extracts at a dose of 200 mg/kg or
2,000 mg/kg after being fed a control diet or NUTRIOSE-containing diet for 2 wk; N-
NOR: Group fed with NUTRIOSE (control diet þ NUTRIOSE 10%) for 2 wk; G0.2: Group
treated with ginseng extract (200 mg/kg) after being fed with a control diet for 2 wk;
G2: Group treated with ginseng extract (2,000 mg/kg) after being fed with a control
diet for 2 wk. All values are presented as mean  standard deviation (n ¼ 5).
Fig. 6. Effect of NUTRIOSE on the intestinal bacterial metabolic conversion of ginse-
noside Rb1 to ginsenoside Rd in rat fecal microbiota cultured in general anaerobic
medium. All values are presented as mean  standard deviation (n ¼ 4). * p < 0.05
compared with dextrose.
J Ginseng Res 2014;38:203e2072062.8. Statistical analysis
Statistical analysis was performed using a one-way analysis of
variance (ANOVA; IBM SPSS version 20.0; IBM Corp., Armonk, NY,
USA). A p value < 0.05 was considered statistically signiﬁcant.3. Results
3.1. Fecal metabolic activities of rats for ginsenoside Rb1 in vitro
To conﬁrm the ability of intestinal microﬂora to metabolize
ginsenosides to ginsenoside Rd, wemeasured ginsenoside Rd levels
after exposure of rat feces to ginsenoside Rb1 (Fig. 2). The activity of
feces in metabolizing ginsenoside Rb1to ginsenoside Rd ranged
from 927 nmol/h/g to 970 nmol/h/g, and the mean activity was
955 nmol/h/g.Fig. 5. Pharmacokinetic study of ginsenoside Rd in rats orally administered ginseng
extract with or without NUTRIOSE. Rats were orally administered ginseng extracts at a
dose of 2,000 mg/kg after being fed a control or NUTRIOSE-containing diet for 2 wk.
G2: Group treated with ginseng extract after being fed a control or NUTRIOSE-con-
taining diet for 2 wk; N2.5-G2: Group treated with ginseng extract after being fed with
NUTRIOSE (control diet þ NUTRIOSE 2.5%) for 2 wk; N5-G2: Group treated with
ginseng extract after being fed with NUTRIOSE (control diet þ NUTRIOSE 5%) for 2 wk;
N10-G2: Group treated with ginseng extract after being fed with NUTRIOSE (control
diet þ NUTRIOSE 10%) for 2 wk. All values are presented as mean  SD (n ¼ 5).3.2. Pharmacokinetic study of ginsenoside Rd in rats orally treated
with ginsenoside Rb1 or ginseng extract
To investigate whether the metabolite ginsenoside Rd is absor-
bed into the blood in rats orally administeredwith ginsenoside Rb1,
we orally administered ginsenoside Rb1 (200 mg/kg) or ginseng
extract (200 mg/kg or 2,000 mg/kg) to rats and then periodically
measured the plasma concentration of ginsenoside Rd, which is a
ginsenoside Rb1 metabolite (Fig. 3). When the rats were adminis-
tered with ginsenoside Rb1 (200 mg/kg), the Tmax of ginsenoside
Rd was 10.6  2.3 h and the Cmax and AUC of ginsenoside Rd were
72.4 31.6 ng/mL and 663.9 285.3ng h/mL, respectively (Table 1).
When ginseng extract was administered at 200 mg/kg or
2,000mg/kg, the Cmax and AUC of ginsenoside Rdwere found to be
690.4  473.0 ng/mL and 8974.2  379.9 ng h/mL, respectively, in
rats treated with 200 mg/kg ginseng extract, and 906.5  330.2 ng/
mL and 11377.3  4470.2 ng h/mL, respectively, in rats treated with
2,000mg/kg ginseng extract, respectively (Fig. 4, Table 1). However,
the differences in Cmax and AUC of ginsenoside Rd between rats
treated with 200 mg/kg and 2,000 mg/kg ginseng extract were not
signiﬁcant.
3.3. Effect of NUTRIOSE on the pharmacokinetic parameters of
ginsenoside Rd in rats orally treated with ginseng extract
To understand the effect of diet on the absorption of the
metabolite ginsenoside Rd into the blood, we measured the plasma
concentration of ginsenoside Rd in ginseng extract-treated rats fed
with or without pretreatment with NUTRIOSE for 2 wk. We
detected ginsenoside Rd when ginseng extract was orally admin-
istered in rats both with and without NUTRIOSE pretreatment
(Fig. 5). We could detect ginsenoside Rd at 2 h after administration
of ginseng extract in rats not fed NUTRIOSE. We also found that
NUTRIOSE increased the blood concentration of ginsenoside Rd as
compared with to that in the normal control group by up to 30%,
although the difference between groups was not statistically sig-
niﬁcant due to large individual variations (Table 1).
3.4. Effect of NUTRIOSE on the metabolic conversion of ginsenoside
Rb1 to ginsenoside Rd by rat fecal microﬂora cultured in GAM
To further investigate whether NUTRIOSE could induce rat fecal
metabolic activity in the conversion of ginsenoside Rb1 to ginse-
noside Rd, we cultured fecal microbiota of rats in GAM broth with
or without NUTRIOSE for 24 h and measured the ginsenoside Rd-
K.-A. Kim et al / NUTRIOSE and gensenoside Rd 207forming activity (Fig. 6). The cultured fecal microbiota of rats
potently hydrolyzed ginsenoside Rb1 to ginsenoside Rd when
NUTRIOSEwas added.When rat fecal microbiotawas cultured in 1%
NUTRIOSE-containing GAM broth, the metabolism of ginsenoside
Rb1 to ginsenoside Rd was induced 3.4 fold (3.4  1.8, p ¼ 0.04)
compared with microbiota cultured in dextrose-containing GAM
broth.
4. Discussion
Ginseng contains many hydrophilic ginsenosides, which are
metabolized to hydrophobic bioactive compounds before absorp-
tion into the blood [2]. For example, ginsenosides Ra1, Ra, Rb1, Rb2,
Rc, and Rd are metabolized to compound K via ginsenoside Rd by
intestinal microbiota of humans and rats. Therefore, to understand
the complete spectrum of the pharmacological activities of ginseng,
it is important to ﬁrst understand the metabolism of ginsenosides
and study the absorption pattern of the metabolites into systemic
circulation. In the present study, we measured ginsenoside Rd, a
metabolite of ginsenoside Rb1, in rats orally treated with ginse-
noside Rb1. We could also detect the important metabolite ginse-
noside Rd after exposure of ginsenoside Rb1 to intestinal
microbiota. This metabolite was also detected in rats orally treated
with ginseng extract. In previous clinical studies, ginsenoside Rd
was detected when G115, a ginseng saponin fraction, was admin-
istered orally [20]. We detected ginsenoside Rd 8 h after adminis-
tration in the blood of ginsenoside Rb1-treated rats. However, in
the blood of ginseng extract-treated rats, ginsenoside Rd was
detected within 2 h after administration. The rapid absorption of
ginsenoside Rd in ginseng extract-treated rats as compared to that
in ginsenoside Rb1-treated rats should be due to the higher gin-
senoside Rd content in the ginseng extract. We also analyzed the
difference in the systemic absorption of the fecal metabolite gin-
senoside Rd between rats orally treated with ginsenoside Rb1 and
ginseng extract. The Tmax values of ginsenoside Rd were not
different between ginsenoside-Rb1-treated and ginseng-extract-
treated rats. When the dosage of ginseng extract was increased,
Tmax was longer. However, when the same ginsenoside Rb1 and
ginseng extract dosage was orally administered, the AUC and Cmax
of ginsenoside Rd were 13.5-fold higher in ginseng extract-treated
rats than in ginsenoside Rb1-treated rats. These results may be due
to ginsenoside Rd contained in the ginseng extract. Furthermore,
when the dosage of ginseng extract was increased 10-fold, the AUC
of ginsenoside Rd did not signiﬁcantly increase. These results
suggest that when ginsenoside Rb1 was administered orally, the
absorption of the metabolite ginsenoside Rd would depend on the
metabolic conversion of ginsenoside Rb1 to ginsenoside Rd by in-
testinal microbiota. Therefore, to increase the rate of absorption of
ginsenoside Rd into the blood, intestinal bacterial metabolic acti-
vation of ginsenoside Rb1 to ginsenoside Rd may be induced. In the
present study, we investigated the effect of a prebiotic, NUTRIOSE,
on intestinal bacterial metabolic activity. When the intestinal
microbiota of rats were cultured in NUTRIOSE-containing GAM,
NUTRIOSE induced the metabolic conversion of ginsenoside Rb1 to
ginsenoside Rd. These results suggest that the prebiotic NUTRIOSE
may promote the ginsenoside-metabolizing enzyme activity of
gastrointestinal microbiota, and that NUTRIOSE-induced micro-
biota are capable of further potentiating the metabolic conversion
of ginsenosides to ginsenoside Rd. We also performed a pharma-
cokinetic study of ginseng extract in rats fed with NUTRIOSE for
2 wk. Supplementation of NUTRIOSE in the diet signiﬁcantly
increased the AUC and Cmax of ginsenoside Rd in a NUTRIOSE
content dependent manner and accelerated this process. Supple-
mentation of 10% NUTRIOSE in the diet caused AUC and Cmax ofginsenoside Rd to increase 1.34-fold. Furthermore, Tmax was
shorter in NUTRIOSE-fed rats than in normal diet-treated ones.
In conclusion, the absorption of bioactive metabolite ginseno-
side Rd in rats orally administered with ginsenoside Rb1 or ginseng
extract was dependent on the metabolic activity of gastrointestinal
microﬂora. Furthermore, oral administration of a prebiotic
NUTRIOSE can stimulate the intestinal bacterial metabolic conver-
sion of ginsenoside Rb1 to ginsenoside Rd to improve the absorp-
tion of ginsenoside Rd.Conﬂicts of interest
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